Human VEGF-C DuoSet ELISA, 15 Plate

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human VEGF-C DuoSet ELISA, 15 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: VEGFC

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human VEGF-C DuoSet ELISA, 15 Plate

• Flt4 ligand
• Flt4-L
• vascular endothelial growth factor C
• Vascular endothelial growth factor-related protein
• VEGFC
• VEGF-C
• VRPFLT4 ligand DHM

Background

Vascular endothelial growth factor C (VEGF-C) is a homodimeric ligand of VEGF R3/Flt-4 and is synthesized with N- and C-terminal propeptides. Fully processed VEGF-C containing only the VEGF homology domain can additionally bind and activate VEGF R2/KDR/Flk-1. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis. Both the ligand and receptor are usually co-expressed at sites of lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, neoangiogenesis, and vessel sprouting, resulting in enhanced lymph flow and metastasis to regional lymph nodes.

Publications for VEGF-C (DY752B)(13)

Publications using DY752B

• Shams, S;Stilhano, RS;Silva, EA; Harnessing EGLN1 Gene Editing to Amplify HIF-1 alpha and Enhance Human Angiogenic Response bioRxiv : the preprint server for biology 2023-05-30 [PMID: 37398294] (Human)
• J Jiang, X Cong, S Alageel, U Dornseifer, AF Schilling, E Hadjipanay, HG Machens, P Moog In Vitro Comparison of Lymphangiogenic Potential of Hypoxia Preconditioned Serum (HPS) and Platelet-Rich Plasma (PRP) International Journal of Molecular Sciences, 2023-01-19;24(3):. 2023-01-19 [PMID: 36768283] (Human)
• Y Ding, L Oliveira-F, E Vettorazzi, K Legler, K Milde-Lang, L Woelber, A Jaeger, K Prieske, V Mueller, B Schmalfeld, S Kuerti VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients PLoS ONE, 2022-06-10;17(6):e0269680. 2022-06-10 [PMID: 35687576] (Human)
• JP Lapuente, A Blázquez-M, J Marco-Brua, G Gómez, P Desportes, J Sanz, P Fernández, M García-Gil, F Bermejo, JV San Martín, A Algaba, JC De Gregori, D Lapuente, A De Gregori, B Lapuente, MV Andrés, A Anel Cytokine Profile and Anti-Inflammatory Activity of a Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells (PRS CK STORM) Biomolecules, 2022-03-31;12(4):. 2022-03-31 [PMID: 35454123] (Human)
• L Cristinzia, R Poto, G Criscuolo, AL Ferrara, MR Galdiero, L Modestino, S Loffredo, A de Paulis, G Marone, G Spadaro, G Varricchi IL-33 and Superantigenic Activation of Human Lung Mast Cells Induce the Release of Angiogenic and Lymphangiogenic Factors Cells, 2021-01-12;10(1):. 2021-01-12 [PMID: 33445787] (Human)
• G Varricchi, S Loffredo, L Bencivenga, AL Ferrara, G Gambino, N Ferrara, A de Paulis, G Marone, G Rengo Angiopoietins, Vascular Endothelial Growth Factors and Secretory Phospholipase A2 in Ischemic and Non-Ischemic Heart Failure J Clin Med, 2020-06-19;9(6):. 2020-06-19 [PMID: 32575548] (Human)
• G Varricchi, S Loffredo, F Borriello, A Pecoraro, F Rivellese, A Genovese, G Spadaro, G Marone Superantigenic Activation of Human Cardiac Mast Cells Int J Mol Sci, 2019-04-12;20(8):. 2019-04-12 [PMID: 31013832] (Human)
• PD Ndiaye, M Dufies, S Giuliano, L Douguet, R Grépin, J Durivault, P Lenormand, N Glisse, J Mintcheva, V Vouret-Cra, B Mograbi, M Wurmser, D Ambrosetti, N Rioux-Lecl, P Maire, G Pagès VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness Theranostics, 2019-01-21;9(3):661-675. 2019-01-21 [PMID: 30809300] (Human)
• J Bourland, J Fradette, FA Auger Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development Sci Rep, 2018-09-04;8(1):13191. 2018-09-04 [PMID: 30181613] (Human)
• M Lupu-Plesu, A Claren, S Martial, PD N'Diaye, K Lebrigand, N Pons, D Ambrosetti, I Peyrottes, J Feuillade, J Hérault, M Dufies, J Doyen, G Pagès Effects of proton versus photon irradiation on (lymph)angiogenic, inflammatory, proliferative and anti-tumor immune responses in head and neck squamous cell carcinoma Oncogenesis, 2017-07-03;6(7):e354. 2017-07-03 [PMID: 28671677] (Human)
• Kumar N, Moideen K, Sivakumar S, Menon P, Viswanathan V, Kornfeld H, Babu S Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors. J Infect, 2016-10-04;74(1):10-21. 2016-10-04 [PMID: 27717783] (Human)
• Kumar N, Banurekha V, Nair D, Babu S Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis. PLoS ONE, 2016-01-04;11(1):e0146318. 2016-01-04 [PMID: 26727122] (Human)
• Grepin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E, Scoazec J, Negrier S, Simonnet H, Pages G The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res, 2013-12-12;74(3):873-83. 2013-12-12 [PMID: 24335961] (Human)

FAQs for VEGF-C (DY752B). (Showing 1 - 2 of 2 FAQs).

1. I was wondering if you know of any blocking antibodies against IL-6 or VEGF-C that can be used in cell culture to quench these cytokines?
   • We have no antibodies that are currently known to show blocking antibodies to VEGF-C. Please see this link to our IL-6 antibodies with blocking/neutralizing activity can be found at this link.
2. What is the difference between the Quantikine and Duoset ELISA kits?
   • Our Quantikine kits are fully optimized and validated for the sample types listed on the product specific webpage and datasheet, as this can vary between kits. Each kit is supplied ready to use with one pre-coated 96-well plate, a detection antibody directly conjugated to HRP, and all other necessary reagents. These kits are ideal for researchers who want the convenience of a ready to use and optimized ELISA product. Some of these kits are also available prepackaged in larger 6 and 50 plate sizes.Our DuoSet Kits, in contrast, are ELISA development kits containing the capture and detection antibody, the mass-value calibrated standard, and streptavidin-HRP to prepare approximately 5 or 15 plates. Ancillary reagents will need to be used/purchased, and for most kits, we will recommend one of our Ancillary Reagent Kits, which contain the reagents we use ourselves in-house. DuoSet kits are validated only for cell culture supernatant samples and therefore require further development and validation for accurate measurement in more complex samples such as serum and plasma. Our DuoSet Kits offer an economical, flexible alternative for the experienced ELISA user.

Bioinformatics

• Gene Symbol: VEGFC